Growth Metrics

Biogen (BIIB) Short term Debt (2016 - 2025)

Biogen has reported Short term Debt over the past 14 years, most recently at $150.0 million for Q2 2025.

  • Quarterly results put Short term Debt at $150.0 million for Q2 2025, changed N/A from a year ago — trailing twelve months through Jun 2025 was $150.0 million (changed N/A YoY), and the annual figure for FY2024 was $1.7 billion, up 1065.73%.
  • Short term Debt for Q2 2025 was $150.0 million at Biogen, down from $1.7 billion in the prior quarter.
  • Over the last five years, Short term Debt for BIIB hit a ceiling of $1.7 billion in Q4 2024 and a floor of $150.0 million in Q4 2023.
  • Median Short term Debt over the past 4 years was $574.6 million (2021), compared with a mean of $761.9 million.
  • Peak annual rise in Short term Debt hit 1065.73% in 2024, while the deepest fall reached 1065.73% in 2024.
  • Biogen's Short term Debt stood at $999.1 million in 2021, then crashed by 84.99% to $150.0 million in 2023, then surged by 1065.73% to $1.7 billion in 2024, then plummeted by 91.42% to $150.0 million in 2025.
  • The last three reported values for Short term Debt were $150.0 million (Q2 2025), $1.7 billion (Q4 2024), and $150.0 million (Q4 2023) per Business Quant data.